Novel Liquid Biopsy Technology Lowers Barriers for More Efficient Cancer Diagnostics

A novel liquid biopsy technology is set to advance cancer diagnostics and monitoring by overcoming the long-standing challenge of simultaneously achieving high sensitivity, broad coverage, and simple workflow. A team of researchers from Genomill Health Inc., the University of Turku, and the TYKS Turku University Hospital, Finland, benchmarked this new method, Bridge Capture, against two market-leading tools Their analysis, appearing in The Journal of Molecular Diagnostics, published by Elsevier, highlights the method’s simplicity, cost-efficiency, reproducibility, and scalability, making it well suited for routine clinical testing, disease monitoring, and treatment selection.

Cancer diagnostics are shifting from tissue to liquid biopsies. This minimally invasive approach is fast and can provide a comprehensive overview of tumor genetics. However, today’s liquid biopsies come with key performance challenges.

“Fast and sensitive tests usually cover only few variants that require prior information from a tissue biopsy. Other methods detect a wide range of variants, but require complex workflows, leading to long turnaround times, higher costs, and greater risk of human error. As a result, clinics often need different assays for early detection, treatment selection, or disease monitoring, compromising between sensitivity, speed, and the number of variants they can investigate,” explains CEO of Genomill Health, Inc. (Turku, Finland) Manu Tamminen, PhD.

To address this challenge, Bridge Capture, a targeted next-generation sequencing method, was developed. This study evaluated Bridge Capture using contrived colorectal cancer samples mimicking circulating tumor DNA (ctDNA) across a wide range of variant allele frequencies. The performance of Bridge Capture was benchmarked against two leading commercial liquid-biopsy assays (Archer LIQUIDPlex and Illumina AmpliSeq CHPv2). Bridge Capture showed strong concordance with both assays while detecting the lowest variant allele frequency, demonstrating its superior sensitivity for rare ctDNA variants.

“The technology scales from compact hotspot panels to much larger content without changing the core workflow. That means one method can serve both today’s focused clinical assays and tomorrow’s broader panels,” notes Dr. Tamminen.

Practical usability

The performance of Bridge Capture was also assessed for practical usability. Bridge Capture maintained near-identical results even when read depth was reduced ten-fold, supporting effective use of sequencing depth. Lead co-author Anttoni Korkiakoski, senior bioinformatics specialist and PhD candidate, Genomill Health Inc. and Department of Biology, University of Turku, points out, "Because Bridge Capture uses sequencing capacity very efficiently, you can get low variant allele frequency calls without the need for deep sequencing. That directly translates into lower per-sample cost and opens high-sensitivity testing to labs with limited sequencing budgets.”

Interlaboratory testing provided consistent results, and the results were reproducible between manual and automated workflows, showing robust reproducibility and applicability. As cancer testing is increasingly moving from large, centralized laboratories to smaller decentralized sites, a simple, versatile workflow that performs efficiently on low- to mid-throughput instruments enables cost-effective liquid biopsy testing closer to the patient.

“Bridge Capture is built for the reality of clinical sequencing today: labs need sensitivity for rare variants, but they also need workflows that are simple, fast, and cost-predictable. Our results show you don’t have to trade one for the other anymore,” notes inventor of the technology Juha-Pekka Pursiheimo, PhD, Genomill Health Inc.

Lead co-author Simona Adamusová, laboratory specialist and PhD candidate, Genomill Health Inc. and Department of Biology, University of Turku, adds, “What mattered to us wasn’t just performance in our own hands—it was whether another lab could pick it up just like that and get a corresponding answer. The reproducibility data confirm this is the case.”

Dr. Tamminen concludes, “We were particularly impressed with how well Bridge Capture performed against established commercial technologies, especially its ability to detect very low variant allele frequencies. As the method scales to larger panels while keeping a simple workflow, we see strong potential for broader applications, including early cancer detection.”

Notes for editors

The article is “Bridge Capture Permits Cost-Efficient, Rapid and Sensitive Molecular Precision Diagnostics,” by Simona Adamusová, Anttoni Korkiakoski, Nea Laine, Anna Musku, Tuula Rantasalo, Jorma Kim, Juuso Blomster, Jukka Laine, Tatu Hirvonen, Juha-Pekka Pursiheimo, and Manu Tamminen (https://doi.org/10.1016/j.jmoldx.2025.09.006). The article appears in volume 28, issue 1 (January 2026) of The Journal of Molecular Diagnostics, published by Elsevier.

The article is openly available at https://www.jmdjournal.org/article/S1525-1578(25)00249-1/fulltext.

Full text of the article is also available to credentialed journalists upon request. Contact Eileen Leahy at +1 732 406 1313 or [email protected] to request a PDF of the article or more information. Journalists wishing to interview the study authors should contact Manu Tamminen, PhD, at [email protected].

This study was supported by venture capital from Voima Ventures (Helsinki, Finland), Avohoidon Tutkimussäätiö (Espoo, Finland), Business Finland (Helsinki, Finland), and Almaral (Kaarina, Finland).

About The Journal of Molecular Diagnostics

The Journal of Molecular Diagnostics, the official publication of the Association for Molecular Pathology, co-owned by the American Society for Investigative Pathology, and published by Elsevier, seeks to publish high quality original papers on scientific advances in the translation and validation of molecular discoveries in medicine into the clinical diagnostic setting, and the description and application of technological advances in the field of molecular diagnostic medicine. The editors welcome review articles that contain: novel discoveries or clinicopathologic correlations, including studies in oncology, infectious diseases, inherited diseases, predisposition to disease, or the description of polymorphisms linked to disease states or normal variations; the application of diagnostic methodologies in clinical trials; or the development of new or improved molecular methods for diagnosis or monitoring of disease or disease predisposition. www.jmdjournal.org

關於 Elsevier

身為科學資訊與分析的全球領導者，Elsevier 協助研究人員與醫療照護專業人員推動科學發展，改善醫療成果，造福社會。我們以可信賴、以實證為基礎的內容和先進的 AI 數位技術為基礎，透過創新的解決方案促進洞察力和關鍵決策。

140 多年來，我們一直為研究和醫療保健界的工作提供支援。我們全球 9,500 名員工，包括 2,300 名技術人員，致力於支援研究人員、圖書館館長、學術領袖、資金提供者、政府、研發密集型公司、醫生、護士、未來醫療保健專業人員和教育工作者的重要工作。我們的 2,900 種科學期刊和經典參考工具書包括其領域中最重要的書籍，包括 Cell Press、The Lancet 和 Gray's Anatomy。 我們與愛思唯爾基金會 (Elsevier Foundation) 合作，與我們服務的社群攜手合作，在發展中國家和世界各地的科學、研究和醫療保健領域推動包容性和多樣性。 Elsevier 是 RELX 的一部分，RELX 是一家為專業和商業客戶提供以資訊為基礎的分析和決策工具的全球供應商。有關我們的工作、數位解決方案和內容的更多資訊，請造訪 www.elsevier.com 。